GPNMB tracked PIKfyve inhibitor activity in laboratory studies and healthy volunteers
Original source
Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB): A Translational Pharmacodynamic Biomarker for PIKfyve Inhibition With VRG50635. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Study type
- Clinical trial
- Studied in
- Human, Mouse
- Trial registration
- NCT06286475
GPNMB increased after treatment with VRG50635, a PIKfyve inhibitor pro-drug being developed for amyotrophic lateral sclerosis (ALS). The response was seen in cells, neurons, rodents and in blood and cerebrospinal fluid from healthy adults. The findings support GPNMB as a pharmacodynamic biomarker for measuring the drug’s activity in clinical trials.
Why this matters
GPNMB could help researchers confirm whether VRG50635 is reaching and affecting its intended biological pathway. This study did not test whether the drug improves ALS symptoms or slows disease, so it does not change treatment for people with ALS.
Limitations and context
This was a translational biomarker study involving laboratory models, rodents and two studies in healthy adults. The reported clinical results do not establish safety or benefit in people with ALS, and the source does not provide the clinical study sizes or treatment outcomes. Further ALS trials would be needed to determine whether the biomarker response predicts clinical effects.